Asco 2023 – deep and early responses lift hopes at Effector
New data with a novel RNA translation regulator gave the stock a pre-Asco boost, but the micro-cap company needs to keep the momentum going.
Asco 2023 preview – a microcap winner
One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.
Spac listings slow as the hunt for deals continues
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.